Company Overview and News

14
Bajaj Finance surpasses Axis Bank in m-cap ranking

2018-06-22 moneycontrol
Bajaj Finance has surpassed Axis Bank in terms of market capitalisation, following a surge in its share price which hit a 52-week high during the day today. At the end of session today, market valuation of Bajaj Finance stood at Rs 1,34,952.29 crore, which was Rs 227.16 crore more than that of Axis Bank's Rs 1,34,725.13 crore m-cap.
500820 AXB HCTHY HNDZY ASIANPAINT 532215 AXBKY AXBA BAJFINANCE AXISBANK HCLTECH 532281 BJJQY 500034 500188 HINDZINC

6
Fear and loathing in troubled Thoothukudi

2018-05-29 livemint
“Four hundred beds (worth Rs50 lakh) in this hospital were sponsored by Sterlite Industries,” reads a plaque, written in Tamil, on the wall facing the entrance to the fifth floor of the Government Medical College and Hospital in Thoothukudi.
HNDZY MRZUY VEDL 532500 VED MARUTI LNSTY 500570 TATAMOTORS 500188 HINDZINC SBAZ TTM

14
Anil Agarwal wants to build Vedanta into giant producer of commodities to rival majors

2018-05-27 livemint
London: Billionaire industrialist Anil Agarwal plans to leave behind a legacy: an Indian resources group to rival the world’s biggest.
AULGF VED AAUKF AU HNDZY AAL AGG NGLOY VEDL 500188 HINDZINC

1
Hind Zinc slumps after muted Q4

2018-05-02 premium.thehindubusinessline
The stock of Hindustan Zinc fell by 5.8 per cent on Wednesday, owing to a drop in the March quarter net profit by 18 per cent y-o-y. The weak production guidance given by the company for fiscal 2018-19 has further dampened sentiments. However, a ramp-up in production in the company’s underground mines, higher consistency in grade levels and expected lower cost of production over the next two to three years, remain positives for the stock.
HNDZY 500188 HINDZINC

43
Sensex ends flat ahead of Fed rate decision, but Mid-Smallcap indices slip sharply

2018-05-02 moneycontrol
Benchmark indices ended rangebound session on a flat note Wednesday but the broader markets underperformed, with the Nifty Midcap index falling 1.5 percent and BSE Smallcap declining over a percent amid earnings.
INDIANB 500325 HCTHY JUSTDIAL 532483 532281 EICHERMOT RLNIY AXB JETAIRWAYS YYBKY CNRYY 500182 AXBA TATASTEEL FORTIS TATLY HCLTECH 500180 KOTAKBANK 534809 PCJEWELLER CANBK 500188 HINDZINC GODREJIND RELIANCE 532617 532814 HNDZY 532215 505200 532541 500470 535648 AXISBANK RIGD HDFCBANK HEROMOTOCO YESBANK NIITTECH INDIGO ECQRY KMBKY IBN 532648 532843 539448 AXBKY ICICIBANK TTST HDB 532174 HRTQY 500247 500164 JSTQY

1
Hindustan Zinc Limited - Financial Result Updates

2018-05-02 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
HNDZY 500188 HINDZINC

1
Hindustan Zinc hits 3-week low

2018-05-02 thehindubusinessline
The company, a unit of Vedanta Ltd, has posted a 18 per cent drop in fourth-quarter net profit.
HNDZY VEDL 500188 HINDZINC

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...